204 related articles for article (PubMed ID: 38251484)
1. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study.
Golder V; Kandane-Rathnayake R; Huq M; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Sockalingam S; Navarra SV; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand EF;
Lancet Rheumatol; 2019 Oct; 1(2):e103-e110. PubMed ID: 38229337
[TBL] [Abstract][Full Text] [Related]
3. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
Cunha RN; Saraiva L; Jesus D; Doria A; da Silva JP; Inês LS
Rheumatology (Oxford); 2023 Nov; 62(11):3627-3635. PubMed ID: 36847423
[TBL] [Abstract][Full Text] [Related]
4. Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study.
de Luca Montes RA; Huq M; Godfrey T; Oon S; Calderone A; Kandane-Rathnayake R; Louthrenoo W; Luo SF; Jan Wu YJ; Golder V; Lateef A; Navarra SV; Zamora L; Hamijoyo L; Sockalingam S; An Y; Li Z; Katsumata Y; Harigai M; Chan M; Goldblatt F; O'Neill S; Lau CS; Cho J; Hoi A; Karyekar CS; Morand EF; Nikpour M
Adv Rheumatol; 2024 May; 64(1):38. PubMed ID: 38720354
[TBL] [Abstract][Full Text] [Related]
5. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.
Hao Y; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Zhang Z
Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35241499
[TBL] [Abstract][Full Text] [Related]
6. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study.
Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Cho J; Lateef A; Hamijoyo L; Luo SF; Wu YJ; Navarra SV; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake BMDB; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Yu D; Karyekar CS; Sing Lau C; Monk JA; Nikpour M; Hoi A; Morand EF;
Lancet Rheumatol; 2022 Dec; 4(12):e822-e830. PubMed ID: 38261390
[TBL] [Abstract][Full Text] [Related]
7. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
Nikoloudaki M; Nikolopoulos D; Koutsoviti S; Flouri I; Kapsala N; Repa A; Katsimbri P; Theotikos E; Pitsigavdaki S; Pateromichelaki K; Bertsias A; Elezoglou A; Sidiropoulos P; Fanouriakis A; Boumpas D; Bertsias G
Front Immunol; 2022; 13():1074044. PubMed ID: 36685524
[TBL] [Abstract][Full Text] [Related]
8. Predicting flares in patients with stable systemic lupus erythematosus.
Cho J; Lahiri M; Teoh LK; Dhanasekaran P; Cheung PP; Lateef A
Semin Arthritis Rheum; 2019 Aug; 49(1):91-97. PubMed ID: 30660381
[TBL] [Abstract][Full Text] [Related]
9. Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study.
Connelly K; Kandane-Rathnayake R; Hoi A; Louthrenoo W; Hamijoyo L; Cho J; Lateef A; Fen Luo S; Wu YJ; Li Z; Navarra S; Zamora L; Sockalingam S; Hao Y; Zhang Z; Katsumata Y; Harigai M; Oon S; Chan M; Chen YH; Bae SC; O'Neill S; Goldblatt F; Kikuchi J; Takeuchi T; Ling Ng KP; Tugnet N; Basnayake BMDB; Ohkubo N; Tanaka Y; Sing Lau C; Nikpour M; Golder V; Morand EF;
Lancet Rheumatol; 2022 Dec; 4(12):e831-e841. PubMed ID: 38261391
[TBL] [Abstract][Full Text] [Related]
10. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A
Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
[TBL] [Abstract][Full Text] [Related]
11. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
[TBL] [Abstract][Full Text] [Related]
12. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus.
Kikuchi J; Hanaoka H; Saito S; Oshige T; Hiramoto K; Kaneko Y; Takeuchi T
Rheumatology (Oxford); 2022 Aug; 61(9):3777-3791. PubMed ID: 35015824
[TBL] [Abstract][Full Text] [Related]
13. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study.
Golder V; Kandane-Rathnayake R; Huq M; Nim HT; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Sockalingam S; Navarra SV; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand EF;
Lancet Rheumatol; 2019 Oct; 1(2):e95-e102. PubMed ID: 38229349
[TBL] [Abstract][Full Text] [Related]
14. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
15. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
Pitsigavdaki S; Nikoloudaki M; Garantziotis P; Silvagni E; Repa A; Marangoni A; Flouri I; Avgoustidis N; Parperis K; Fanouriakis A; Govoni M; Sidiropoulos P; Boumpas DT; Bortoluzzi A; Bertsias G
Ann Rheum Dis; 2024 Mar; 83(4):464-474. PubMed ID: 38233103
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of disease flares in a Chinese lupus cohort with low-grade disease activity.
Sun F; Zhao L; Wang H; Zhang D; Chen J; Wang X; Li T; Ye S
Lupus Sci Med; 2022 May; 9(1):. PubMed ID: 35606018
[TBL] [Abstract][Full Text] [Related]
17. Impact of teleconsultation on subsequent disease activity and flares in patients with systemic lupus erythematosus.
Au Eong JTW; Lateef A; Liang S; Lim SHH; Tay SH; Mak A; Cho J
Rheumatology (Oxford); 2022 May; 61(5):1911-1918. PubMed ID: 34554232
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study.
Apostolopoulos D; Kandane-Rathnayake R; Louthrenoo W; Luo SF; Wu YJ; Lateef A; Golder V; Sockalingam S; Navarra S; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Lau CS; Li ZG; Hoi A; Nikpour M; Morand E;
Lancet Rheumatol; 2020 Jan; 2(1):e24-e30. PubMed ID: 38258272
[TBL] [Abstract][Full Text] [Related]
19. Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes.
Pawlak-Buś K; Schmidt W; Leszczyński P
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):949-959. PubMed ID: 36808341
[TBL] [Abstract][Full Text] [Related]
20. Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus.
Smith EMD; Tharmaratnam K; Al-Abadi E; Armon K; Bailey K; Brennan M; Ciurtin C; Gardner-Medwin J; Haslam KE; Hawley D; Leahy A; Leone V; Malik G; McLaren Z; Pilkington C; Ramanan AV; Rangaraj S; Ratcliffe A; Riley P; Sen E; Sridhar A; Wilkinson N; Hedrich CM; Jorgensen A; Beresford MW
Rheumatology (Oxford); 2022 Aug; 61(8):3378-3389. PubMed ID: 34894234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
